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Background. Cannabis is a widely used drug associated with increased risk for psychosis. The dopamine hypothesis of
psychosis postulates that altered salience processing leads to psychosis. We therefore tested the hypothesis that cannabis
users exhibit aberrant salience and explored the relationship between aberrant salience and dopamine synthesis capacity.
Method. We tested 17 cannabis users and 17 age- and sex-matched non-user controls using the Salience Attribution Test,
a probabilistic reward-learning task. Within users, cannabis-induced psychotic symptoms were measured with the
Psychotomimetic States Inventory. Dopamine synthesis capacity, indexed as the inﬂux rate constant Ki
cer, was measured
in 10 users and six controls with 3,4-dihydroxy-6-[18F]ﬂuoro-L-phenylalanine positron emission tomography.
Results. There was no signiﬁcant difference in aberrant salience between the groups [F1,32 = 1.12, p = 0.30 (implicit); F1,32
= 1.09, p = 0.30 (explicit)]. Within users there was a signiﬁcant positive relationship between cannabis-induced psychotic
symptom severity and explicit aberrant salience scores (r = 0.61, p = 0.04) and there was a signiﬁcant association between
cannabis dependency/abuse status and high implicit aberrant salience scores (F1,15 = 5.8, p = 0.03). Within controls, impli-
cit aberrant salience was inversely correlated with whole striatal dopamine synthesis capacity (r =−0.91, p = 0.01), where-
as this relationship was non-signiﬁcant within users (difference between correlations: Z =−2.05, p = 0.04).
Conclusions. Aberrant salience is positively associated with cannabis-induced psychotic symptom severity, but is not
seen in cannabis users overall. This is consistent with the hypothesis that the link between cannabis use and psychosis
involves alterations in salience processing. Longitudinal studies are needed to determine whether these cognitive abnor-
malities are pre-existing or caused by long-term cannabis use.
Received 4 July 2016; Revised 22 July 2016; Accepted 25 July 2016; First published online 15 September 2016
Key words: Addiction, cannabis, dopamine, psychosis, salience.
Introduction
Cannabis is a widely used drug (United Nations Ofﬁce
on Drugs and Crime, 2010) and cannabis may disrupt
reward-based learning (Mendelson et al. 1976; Cherek
et al. 2002; Lane & Cherek, 2002; Lane et al. 2005).
The main psychoactive substance in cannabis is
Δ9-tetrahydrocannabinol (THC) (Wachtel et al. 2002),
an endocannbinoid CB1 receptor partial agonist
(Felder et al. 1992; Sim et al. 1996; Petitet et al. 1998;
Shen & Thayer, 1999; Breivogel & Childers, 2000;
Govaerts et al. 2004; Kelley & Thayer, 2004; Paronis
et al. 2012). Human and animal research indicates
that THC can disrupt reward-based behaviour
(Stiglick & Kalant, 1983; Foltin et al. 1989; Kamien
et al. 1994; Lane & Cherek, 2002; Lane et al. 2004).
The mesolimbic dopamine system mediates reward-
based learning (Berridge & Robinson, 1998), which in
turn is modulated by the endocannabinoid system
(Fernandez-Ruiz et al. 2010; Melis & Pistis, 2012;
Melis et al. 2012).
THC has complex effects on the dopamine system:
studies in rodents indicate that acute administration
increases dopaminergic neuron ﬁring rates (French,
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1997); whilst chronic administration reduces presynap-
tic dopaminergic function (Ginovart et al. 2012). In
humans, acute THC administration has been reported
to increase dopamine release in two out of four studies
(Bossong et al. 2009; Stokes et al. 2009; Barkus et al.
2011; Kuepper et al. 2013), whilst chronic cannabis
use is associated with reductions in dopaminergic
function (Urban et al. 2012; Albrecht et al. 2013;
Bloomﬁeld et al. 2014a, b; Volkow et al. 2014). There
is also evidence that long-term cannabis use is asso-
ciated with attenuated striatal reward processing
(van Hell et al. 2010). These studies provide converging
evidence that cannabis use disrupts reward-based
learning by changes to the dopaminergic system.
Cannabis users are dose-dependently at increased risk
of schizophrenia (Murray et al. in press). Psychosis has
been proposed to reﬂect a state of aberrant salience pro-
cessing driven by elevated dopamine transmission
(Kapur, 2003), and aberrant salience has been related
to the presence of delusions in medicated patients with
schizophrenia (Roiser et al. 2009). Similarly, individuals
at ultra-high risk of psychosis demonstrate aberrant sali-
ence, the degree of which relates to the severity of
delusion-like symptoms (Roiser et al. 2013). Since long-
term, regular cannabis use is associated with increased
risk of psychosis (Murray et al. in press), the aberrant sa-
lience hypothesis predicts that aberrant salience process-
ing is elevated in this group and that this is linked to the
induction of psychotic-like symptoms in cannabis users.
Therefore, we sought to investigate reward-based sa-
lience processing in cannabis users using the Salience
Attribution Test (SAT) (Roiser et al. 2009). The SAT is
a probabilistic reward-learning task featuring com-
pound cue stimuli that vary along two dimensions,
one task-relevant and one task-irrelevant. ‘Adaptive’ re-
ward learning refers to differences in ratings (the expli-
cit measure of learning) and reaction times (RTs) (the
implicit measure of learning) along the task-relevant
cue dimension, i.e. for high-probability reward cue fea-
tures relative to low-probability reward cue features.
‘Aberrant’ reward learning is deﬁned similarly, but
along the task-irrelevant dimension, i.e. differences in
ratings or RTs between cue features that are both asso-
ciated with 50% probability of reward.
We hypothesized that cannabis users would show ele-
vated levels of aberrant salience compared with non-user
controls, and that within the cannabis users aberrant sa-
lience processing would be speciﬁcally associated with
greater severity of transient psychotic phenomena. We
also sought to explore whether users who meet diagnos-
tic criteria for cannabis dependence or abuse [Diagnostic
and Statistical Manual of Mental Disorders, fourth
edition, text revision (DSM-IV-TR) 304.30; 305.20, i.e.
compulsive or periodic harmful use of cannabis despite
signiﬁcant drug-related problems] would exhibit
elevated aberrant salience processing. As a number of
participants had previously undergone 3,4-dihydroxy-
6-[18F]ﬂuoro-L-phenylalanine ([18F]DOPA) positron emis-
sion tomography (PET) in this laboratory (Bloomﬁeld
et al. 2014a, b), we also sought to explore the relationships
between dopamine synthesis capacity and aberrant sali-
ence processing.
Method
Study population
The study was approved by the National Research
Ethics Service (Research Committee Reference 10/
H0713/56) and conducted in accordance with the
Declaration of Helsinki. All participants provided
informed written consent to participate and received
a modest ﬁnancial reimbursement for their time.
Inclusion criteria for all participants were: minimum
age of 18 years and capacity to give written informed
consent. Exclusion criteria for all participants were: cur-
rent or past psychiatric illness (excluding cannabis use
disorders in the cannabis group) using the Structured
Clinical Interview for DSM-IV (SCID) (First et al. 1996);
family history of mental illness in a ﬁrst-degree relative
determined via the Family Interview for Genetic
Studies (NIMH Genetics Initiative, 1992); evidence of
an at-risk mental state for psychosis (Phillips et al.
2000); DSM-IV-TR (American Psychiatric Association,
2005) substance dependency or abuse (other than canna-
bis in the cannabis-user group and nicotine use disorders
for all participants); and signiﬁcant medical illness. None
of the participants was taking psychotropic medication
at the time of study participation.
Detailed drug histories were obtained from all parti-
cipants using the Cannabis Experience Questionnaire
(Barkus et al. 2006), structured interview and timeline
follow-back (Sobell et al. 1996). Lifetime cannabis use
was estimated as the total number of ‘spliffs’ (cannabis
cigarettes; ‘joints’) consumed. The time taken to smoke
an ‘eighth’ of cannabis (1/8 ounce; about 3.5 g, the
standard unit of sale the UK) was chosen as the pri-
mary index of cannabis use because this provides a
measure of the amount of current drug consumption
(shorter time indicating greater consumption). This is
likely to be more accurate than subjective recall of
the number of spliffs consumed because of variability
in cannabis dose between spliffs and inconsistencies
in self-reported cannabis use (Akinci et al. 2001).
Cannabis user group
All cannabis users were recruited by public advertise-
ment. All participants were required to be current, at
least weekly, users of cannabis. Cases were primarily
recruited from an ongoing cohort study (Morgan et al.
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2012). A subsample of users had measurements avail-
able on the induction of psychotic symptoms in re-
sponse to smoking cannabis, which was deﬁned as a
positive change in scores on the psychotic items of the
Psychotomimetic States Inventory (PSI) (Mason &
Wakerley, 2012), measured 5 min after smoking their
usual amount of cannabis (i.e. when acutely intoxicated)
compared with when not intoxicated with the drug.
These users consumed their own cannabis, and subject-
ive ratings were acquired in the environment where
users habitually consumed cannabis (e.g. at home) be-
cause drug effects are typically larger in naturalistic as
opposed to laboratory environments (Barkus et al.
2006). Cannabis-induced psychotic symptoms abated
within 2 h of consumption. The psychotic items from
the PSI covered ‘delusional thinking’, ‘perceptual distor-
tions’, ‘cognitive disorganization’ (thought disorder)
and ‘paranoia’. Each item was rated on a four-point
scale from ‘not at all’ (score = 0) to ‘strongly’ (score =
3). Examples of items include: ‘People can put thoughts
into your mind’ and ‘You can sense an evil presence
around you, even though you cannot see it’. A sample
of the cannabis that each participant smoked was
taken on the day of testing and analysed for levels of
THC (Forensic Science Service, Birmingham, UK).
A total of 12 cannabis users who experienced a posi-
tive change in psychotic symptom severity in response
to cannabis were recruited from the Bloomﬁeld et al.
(2014a, b) study. An additional two users were recruited
from an ongoing study (Morgan et al. 2012). A further
three users were recruited by public advertisement.
Therefore 17, at least weekly, cannabis users are
included in the present study. All cannabis users con-
sumed the drug mixed with tobacco as a spliff.
Control group
Non-user healthy control participants were recruited
from the same geographical area by public advertise-
ment. Controls were required to have no lifetime his-
tory of cannabis dependence or abuse (DSM-IV-TR),
no more than 10 total uses of cannabis in their lifetime,
no report of the induction of psychotic symptoms by
cannabis, and no cannabis use in the preceding 3
months. Community surveys indicate that more than
30% of young adults in England report trying cannabis
in their lifetime (Smith & Flatley, 2012). Control parti-
cipants were therefore permitted to have had minimal
exposure to cannabis to ensure that the control group
was representative of the same general population
from which the cannabis users were recruited.
SAT
The SAT behaviourally measures aberrant salience. A
more detailed description is provided in the original
publication (Roiser et al. 2009) and the online
Supplementary information. In brief, a cue stimulus
appeared on the screen, which could vary across two
dimensions: colour (red or blue) and form (animal or
household object; Fig. 1). Stimulus features on one di-
mension predicted reward availability (e.g. red v. blue:
87.5 v. 12.5%); the other dimension was irrelevant in
terms of reward occurrence (e.g. 50% reward for both
animal and household features). Following the cue, par-
ticipants had to respond to the presentation of a square
(the probe) to win money. Faster responses yielded
higher rewards, but reward was not always available.
If the trial was not reinforced, the message ‘Sorry – no
money available’ was displayed after the probe disap-
peared. If reinforced, ‘hit’ responses (made before the
probe disappeared) that were slower than the partici-
pant’s own mean RT (measured during an earlier prac-
tice session) resulted in the message ‘Hit – good: 10
pence’. For hit responses faster than the participant’s
mean practice RT the following messages appeared:
‘Quick – very good: X pence’ and ‘Very quick – excel-
lent: X pence’. The maximum reward was £1.
Participants performed the task in two separate blocks
of equal length, over which values were averaged.
PET
PET acquisition and analysis were performed as previ-
ously described (Bloomﬁeld et al. 2014a, b) using a
Fig. 1. Salience Attribution Test. Subjects are presented with a ﬁxation cross followed by a cue. They then have to respond to
the solid square as quickly as possible. During 50% of trials, participants are rewarded with money for faster responses, with
the probability of the reward signalled by the cue.
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method that has demonstrated good test–retest reliabil-
ity (Egerton et al. 2010). In brief, subjects underwent
[18F]DOPA scanning on an ECAT HR+ 962 tomograph
(CTI/Siemens, USA). Participants were asked to fast
and abstain from cannabis for 12 h and to refrain
from smoking tobacco for 2 h before imaging. On the
day of PET scanning, urine drug screen (Monitect
HC12; Branan Medical Corporation, USA) conﬁrmed
no recent drug use (other than cannabis in the user
group), and a negative urinary pregnancy test was
required in all female participants. A research clinician
(M.A.P.B.) assessed psychotic symptoms using the
Positive and Negative Syndrome Scale (PANSS) at the
time of scanning. No participants had psychotic symp-
toms at the time of scanning [mean PANSS positive
score cannabis users = 7.4 (S.D. = 0.5); control participants
= 7.3 (S.D. = 0.5)]. Participants received carbidopa 150 mg
and entacapone 400 mg orally 1 h before imaging to
reduce the formation of radiolabelled [18F]DOPA meta-
bolites (Cumming et al. 1993; Guttman et al. 1993). We
performed a 10 min transmission scan before radiotracer
injection for attenuation- and scatter-correction followed
by bolus intravenous injection of approximately 180
MBq of [18F]DOPA. Emission data were acquired for
95 min over 26 frames. Head movement correction was
performed with a wavelet ﬁlter (Turkheimer et al.
1999) and mutual information algorithm (Studholme
et al. 1996). A summation image was created from each
movement-corrected dynamic image using real-time
position management (RPM) (Gunn et al. 1997). We
then deﬁned standardized regions of interest (ROIs) bi-
laterally in the whole striatum in Montreal
Neurological Institute space (Martinez et al. 2003;
Egerton et al. 2010) to create an ROI map. We used stat-
istical parametric mapping software (SPM5; http://ﬁl.ion.
ucl.ac.uk/spm) to normalize the ROI map to each indi-
vidual PET summation image using a template to aid
normalization (Howes et al. 2009, 2011). We calculated
the inﬂux rate constant of [18F]DOPA uptake in each
ROI relative to the cerebellum [Ki
cer (min−1)] using the
Patlak graphical analysis adapted for a reference tissue
input function (Patlak & Blasberg, 1985; Hartvig et al.
1991, 1997; Hoshi et al. 1993).
Statistical analysis
Data were analysed using the Statistical Package for
the Social Sciences (SPSS), version 21 (IBM, USA).
Demographic data were analysed using independent-
samples t tests and χ2 tests. SAT data were analysed
using repeated-measures analysis of variance with
block (1/2) and probability as within-subject variables
and group (cannabis user/control) as the between-
subjects variable. Normality of distributions was
assessed using the one-sample Kolmogorov–Smirnov
test. Salience outcome measures were assessed for
signiﬁcant skew. RT and visual analogue scale (VAS)
aberrant salience scores from the SAT were square
root transformed prior to analysis to reduce skew,
though untransformed values are presented in the
text, ﬁgures and tables for clarity. Relationships be-
tween salience measures, symptoms and dopamine
synthesis capacity were assessed using Pearson’s r.
To determine whether participants consistently
assigned aberrant salience to any particular stimulus
feature, χ2 tests were employed. For all analyses p <
0.05 (two-tailed) was considered signiﬁcant.
Results
Participant characteristics
The mean age of ﬁrst cannabis use was 15.5 (S.D. = 2.0)
years, and the mean duration of at least weekly use
was 5.9 (S.D. = 3.1) years. The mean time taken to
smoke an eighth was 8.3 (S.D. = 7.3) days and mean life-
time exposure was 2850 (S.D. = 2447) spliffs. Six users
met DSM-IV criteria for cannabis dependence or
abuse. Mean time to smoke an eighth was 4.0 (S.D. =
4.3) days in users who met dependency and/or abuse
criteria and 11.0 (S.D. = 8.4) days in users who did not
meet criteria. A total of 17 control participants were
matched to the user group for age (±5 years) and sex.
Participant characteristics are reported in Table 1.
Urine drug screens were positive for THC and negative
for all other substances (amphetamine, opiates, co-
caine, methamphetamine, benzodiazepines) in every
cannabis user and negative for all drugs (including
cannabis) in every control participant. There was no
signiﬁcant group difference in age or sex.
SAT
Behavioural data are presented in Table 2.
RT (implicit salience)
Participants responded faster on high- relative to
low-probability-reinforced trials (F1,31 = 21.4, p < 0.001)
and there was no group × probability interaction (F1,30
= 1.02, p = 0.32). There was no group × block interaction
(F1,32 = 0.05, p = 0.82) and no main effect of group (F1,32
= 1.60, p = 0.22) or block (F1,32 = 2.43, p = 0.13). There
was a signiﬁcant probability × block interaction (F1,32 =
5.28, p = 0.03): across both groups implicit adaptive sali-
ence was signiﬁcantly greater on block 2 than block 1.
There was no signiﬁcant difference in implicit aber-
rant salience between cannabis users and controls
(F1,32 = 1.12, p = 0.30), no group × block interaction
(F1,32 = 1.08, p = 0.31) and no main effect of block
(F1,32 = 1.30, p = 0.26). Participants did not consistently
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respond faster in the context of any particular irrele-
vant stimulus feature (p > 0.05).
VAS (explicit salience)
Across all participants, high-probability-reinforced
trials were rated as being more likely to yield reward
compared with low-probability-reinforced trials (F1,31
= 130.0, p < 0.001). There was no main effect of block
(F1,32 = 3.18, p = 0.08) and no group × block interaction
(F1,32 = 0.38, p = 0.54). There was no signiﬁcant effect
of group on explicit adaptive salience (F1,32 = 0.80, p =
0.38, Fig. 3).
There was no signiﬁcant effect of group on explicit
aberrant salience (F1,32 = 1.09, p = 0.30) and no group ×
block interaction (F1,32 = 0.35, p = 0.56) or main effect
of block (F1,32 = 2.43, p = 0.13). Participants did not con-
sistently rate any particular irrelevant stimulus feature
as more likely to yield reward relative to the others.
Relationship between salience processing and
cannabis use
Within the cannabis user group, there were no signiﬁ-
cant relationships between current cannabis use and
measures of salience processing (implicit adaptive
Table 1. Sample characteristics
Controls (n = 17) Cannabis users (n = 17) pa
Mean age, years (S.D.) 23.9 (4.2) 22.4 (1.9) 0.19
Sex, n 0.44
Female 6 3
Male 11 14
Mean cannabis use, g cannabis/month (S.D.) N.A. 31.8 (38.5) N.A.
Mean THC content of cannabis, % (S.D.) N.A. 7.5 (2.9) N.A.
Mean time to smoke an eighth of cannabis, days (S.D.) N.A. 8.3 (7.3) N.A.
Mean age of onset of regular cannabis use, years (S.D.) N.A. 16.3 (2.0) N.A.
S.D., Standard deviation; N.A., not applicable; THC, Δ9-tetrahydrocannabinol.
a Independent-samples t tests for variables with normal data distributions; Mann–Whitney U tests for variables with non-
normal data distributions; χ2 tests for dichotomous variables.
Table 2. Salience Attribution Test behavioural data
Test Measure Controls (n = 17) Cannabis users (n = 17)
Block 1
RT high probability, ms 300.5 (114.9) 277.5 (111.7)
RT low probability, ms 335.8 (51.4) 304.2 (53.2)
RT adaptive salience, ms 11.2 (21.9) 3.8 (14.2)
RT aberrant salience, ms 12.8 (4.7) 20.8 (19.5)
VAS high probability, mm 55.8 (26.9) 63.0 (19.0)
VAS low probability, mm 14.1 (8.4) 18.0 (12.1)
VAS adaptive salience, mm 41.3 (29.4) 45.7 (25.3)
VAS aberrant salience, mm 16.3 (14.5) 10.4 (9.6)
Block 2
RT high probability, ms 312.9 (56.4) 294.8 (57.5)
RT low probability, ms 332.7 (58.1) 310.8 (67.0)
RT adaptive salience, ms 20.3 (22.4) 14.9 (18.6)
RT aberrant salience, ms 13.4 (15.2) 12.4 (7.7)
VAS high probability, mm 63.3 (24.7) 66.3 (19.8)
VAS low probability, mm 16.3 (9.7) 10.8 (7.6)
VAS adaptive salience, mm 46.3 (26.7) 56.0 (23.1)
VAS aberrant salience, mm 8.7 (6.4) 8.4 (8.6)
SPQ – 19.9 (9.1)
Data are given as mean (standard deviation).
RT, Reaction time; VAS, visual analogue scale; SPQ; Schizotypal Personality Questionnaire.
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salience: r = 0.07, p = 0.79; implicit aberrant salience r =
0.49, p = 0.06; explicit adaptive salience r =−0.46, p =
0.07; explicit aberrant salience r = 0.14, p = 0.61). There
was no signiﬁcant relationship between age of onset
of cannabis use and measures of salience processing
(implicit adaptive salience: r = 0.32, p = 0.23; implicit ab-
errant salience r =−0.18, p = 0.52; explicit adaptive sali-
ence r =−0.12, p = 0.66; explicit aberrant salience r =−
0.12, p = 0.65).
As an exploratory analysis, to examine whether can-
nabis dependency and abuse were associated effects of
salience processing, the cannabis user group was
divided into participants that met DSM-IV-TR criteria
for cannabis dependency and/or abuse (n = 6) and
those who did not meet criteria (n = 11). Within the can-
nabis users there was a signiﬁcant effect of dependency
and abuse diagnosis on implicit aberrant salience, with
elevated implicit aberrant salience in the participants
meeting dependent or abuse criteria relative to cannabis
users not meeting these criteria [F1,15 = 5.8, p = 0.03, effect
size (Cohen’s d) = 1.97], but not on the other outcome
measures (Fig. 2). However, when the control sample
was included in the analysis, the effect of dependency
or abuse diagnosis on implicit aberrant salience did
not reach the threshold for statistical signiﬁcance [F2,32
= 2.9, p = 0.07, effect size (Cohen’s d) = 1.39].
Relationship between aberrant salience processing
and cannabis-induced psychotic symptoms
Within the cannabis users, 12 experienced cannabis-
induced psychotic symptoms [mean increase in PSI
score = 8.6 (S.D. = 5.6)]. There was a signiﬁcant relation-
ship between cannabis-induced psychotic symptom se-
verity and explicit aberrant salience (r = 0.61, p = 0.04;
Fig. 3). There were no signiﬁcant relationships between
cannabis-induced psychotic symptoms and the other
salience measures (p > 0.05), or between Schizotypal
Personality Questionnaire score and salience measures
(p > 0.05).
Relationship between salience processing and
dopaminergic function
As an exploratory analysis, data are presented on sali-
ence processing and dopaminergic function. Six con-
trols in the present study had participated in the
study of dopaminergic function in cannabis users
(Bloomﬁeld et al. 2014a, b). Both implicit and explicit
adaptive salience was positively correlated with
whole striatal dopamine synthesis capacity, whilst im-
plicit aberrant salience was inversely correlated with
whole striatal dopamine synthesis capacity (Fig. 4;
Table 3).
Of the cannabis users in the present study, 10 had
participated in our previous study of dopaminergic
function in cannabis users. There were no signiﬁcant
relationships between the SAT outcome measures
and dopamine synthesis capacity in the whole striatum
(Table 4). Fisher’s r-to-z transformation was applied to
examine whether differences in the relationships be-
tween dopaminergic functioning and salience process-
ing between users and controls were signiﬁcant
(Table 5). Signiﬁcant differences were found in the rela-
tionships between both implicit adaptive and aberrant
salience processing and dopamine synthesis capacity
in the whole striatum. Speciﬁcally, cannabis use was
associated with the loss of a positive relationship be-
tween implicit adaptive salience and dopamine synthe-
sis capacity, and the loss of an inverse relationship
between implicit aberrant salience and dopamine syn-
thesis capacity.
Discussion
The main ﬁnding from this study is that within canna-
bis users who experienced cannabis-induced psychotic
symptoms, there was a signiﬁcant relationship be-
tween cannabis-induced psychotic symptom severity
and aberrant salience processing, accounting for 37%
of the variance in psychotic symptom severity. Whilst
regular long-term cannabis use was not associated
with statistically signiﬁcant differences in behavioural
measurements of salience processing, which is incon-
sistent with our primary hypothesis, these results
show preliminary evidence of increased aberrant sali-
ence in cannabis users who meet DSM-IV criteria for
Fig. 2. Implicit aberrant salience (ordinate; mm) based in
controls and in cannabis users who meet Diagnostic and
Statistical Manual of Mental Disorders, fourth edition
(DSM-IV) dependency and abuse (n = 6), those who did not
meet criteria (n = 11) and controls. Values are means, with
vertical bars representing standard errors.
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cannabis abuse or dependence (effect size: Cohen’s d =
1.2), suggesting that aberrant salience may only be-
come apparent when there is cannabis dependence.
In an exploratory analysis, within controls there were
positive relationships between both measures of adap-
tive salience and whole striatal dopamine synthesis
capacity, whilst there was an inverse relationship be-
tween implicit aberrant salience and whole striatal
dopamine synthesis capacity. However, no signiﬁcant
relationships between whole striatal dopamine synthe-
sis capacity and salience processing were observed in
cannabis users. The results also indicate a loss of rela-
tionship between implicit salience processing and
dopamine synthesis capacity in the whole striatum
associated with long-term cannabis use.
This is the ﬁrst study to examine aberrant salience
processing in cannabis users. Whilst there was no sign-
iﬁcant difference in aberrant salience between the can-
nabis users and controls, a ﬁnding of increased implicit
aberrant salience in cannabis users who meet
DSM-IV-TR criteria for abuse or dependence compared
with those who do not suggests that cannabis depend-
ence and abuse are associated with increased aberrant
salience. We also found that cannabis-induced psych-
otic symptom severity and explicit aberrant salience
are signiﬁcantly positively correlated, in line with
ﬁndings of a positive relationship between explicit
aberrant salience and delusion-like symptoms in peo-
ple at ultra-high risk of psychosis (Roiser et al. 2013)
and delusional symptoms in people with schizophre-
nia (Roiser et al. 2009). In addition, there were some
novel ﬁndings not predicted by the aberrant salience
hypothesis. These were that in healthy controls,
whole striatal dopamine synthesis capacity was posi-
tively correlated with both measures of adaptive sali-
ence processing and negatively correlated with
implicit aberrant salience. The ﬁnding of opposite rela-
tionships between dopamine synthesis capacity and
salience processing in healthy controls is not predicted
by the aberrant salience hypothesis, where increased
dopamine synthesis capacity is predicted to be related
to increased aberrant salience and not vice versa. Two
studies have assessed previously assessed dopamine
synthesis and aberrant salience. One of these did not
ﬁnd signiﬁcant relationships between the measures
(Roiser et al. 2013) and a more recent, larger study,
reported a positive relationship between right ventral
striatal dopamine synthesis capacity and aberrant sali-
ence (Boehme et al. 2015). However, the former study
did report that higher dopamine synthesis capacity
predicted greater adaptive reward prediction haemo-
dynamic responses in controls, whereas the opposite
relationship applied in the individuals at ultra-high
risk of psychosis, in line with the ﬁndings in control
Fig. 3. Relationship between explicit aberrant salience (mm) and cannabis-induced psychotic symptom severity (positive
change in Psychotomimetic States Inventory Score).
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participants in the current study. Roiser et al. (2013)
speculated that the positive impact of high dopamine
synthesis capacity on motivational salience signalling
may depend on the baseline state of the dopamine sys-
tem, such that in healthy volunteers, high dopamine
synthesis capacity may facilitate the transmission of
motivational salience, potentiating appropriate phasic
signals against a background of relatively low gain or
tonic dopamine release. Taken together with ﬁndings
that there is a loss of relationship between implicit sa-
lience processing and dopamine synthesis capacity in
the whole striatum associated with long-term cannabis
use, and given that the mesolimbic dopamine system
plays a central role in normal salience processing
(Zink et al. 2003) which is modulated by endocannabi-
noid signalling (Fernandez-Ruiz et al. 2010; Melis &
Fig. 4. Relationships between dopamine synthesis capacity (indexed as the inﬂux rate constant Ki
cer) in the whole striatum and
implicit adaptive salience (a) and implicit aberrant salience (b) in controls.
3390 M. A. P. Bloomﬁeld et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291716002051
Downloaded from https://www.cambridge.org/core. Australian Catholic University, on 06 Dec 2017 at 23:59:07, subject to the Cambridge Core terms of use, available at
Pistis, 2012; Melis et al. 2012), this would suggest that
long-term cannabis use may give rise to aberrant sali-
ence by disrupting dopaminergic salience processing.
Alternatively, this may predate the cannabis use,
such that these individuals then experience a greater
reward from smoking cannabis. Whilst the effects of
acute THC on aberrant salience processing using the
SAT have yet to be reported in the literature, and the
case–control design of this study is not able to infer
causality, there is evidence from a study using the odd-
ball task (Bhattacharyya et al. 2012) that THC reduces
latency to non-salient v. salient stimuli in healthy
volunteers, consistent with this interpretation.
However, this phenomenon may not be restricted to
reward-based learning only, as increased speed and
error rates were observed with THC challenge in a
learning and episodic memory task (Curran et al.
2002). Nonetheless, long-term cannabis use has been
associated with impairments in ﬁltering out non-
salient information during a selective attention task
(Solowij et al. 1991) and THC resulted in irrelevant
background visual and auditory stimuli becoming
more salient during the performance of a visual pro-
cessing task (D’Souza et al. 2004).
Adolescence is a period of vulnerability to the devel-
opment of neurocognitive effects associated with can-
nabis use and there is also growing evidence that
cannabis use is associated with multiple cognitive
endophenotypes that are in common with schizophre-
nia such as response inhibition, sustained attention,
working memory and executive function (Solowij &
Michie, 2007). Yet, behavioural studies have
Table 3. Relationships between salience attribution and dopamine synthesis capacity (indexed as Ki
cer) in the striatum in controls who had
previously undergone PET scans (n = 6)
Ki
cer, min−1
RT adaptive
salience
RT aberrant
salience
VAS adaptive
salience
VAS aberrant
salience
Mean (S.D.) r p r p r p r p
0.0132 (0.0014) 0.94 0.006 −0.91 0.01 0.82 0.05 −0.15 0.78
Ki
cer, Inﬂux rate constant; PET, positron emission tomography; RT, reaction time; VAS, visual analogue scale; S.D., standard
deviation.
Table 4. Relationships between salience attribution and dopamine synthesis capacity (indexed as Ki
cer) in the striatum in cannabis users who
had previously undergone PET scans (n = 10)
Ki
cer, min−1
RT adaptive
salience
RT aberrant
salience
VAS adaptive
salience
VAS aberrant
salience
Mean (S.D.) r p r p r p r p
0.0128 (0.0008) 0.27 0.45 −0.11 0.77 0.55 0.10 0.22 0.55
Ki
cer, Inﬂux rate constant; PET, positron emission tomography; RT, reaction time; VAS, visual analogue scale; S.D., standard
deviation.
Table 5. Fisher’s r-to-z transformation to examine signiﬁcant differences in the relationships between salience processing and striatal
dopamine synthesis capacity in cannabis users and controls
RT adaptive
salience
RT aberrant
salience
VAS adaptive
salience
VAS aberrant
salience
ROI z p z p z p z p
Striatum 2.12 0.03 −2.05 0.04 0.78 0.44 −0.54 0.59
RT, Reaction time; VAS, visual analogue scale; ROI, region of interest.
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demonstrated that acute THC challenge produces tran-
sient, acute psychotic reactions, the extent of which are
unrelated to the degree of cognitive impairment or
anxiety. There is a large body of evidence describing
the vulnerability of adolescents to impaired cognition,
across a range of domains, associated with cannabis
use (Jager & Ramsey, 2008). Animal studies indicate
that brain CB1 receptor levels peak in early adolescence
(Belue et al. 1995) and humans exposed to cannabis in
adolescence are more likely to have impaired neuro-
cognitive function than individuals exposed in adult
life (Fontes et al. 2011). Furthermore, there is evidence
that neurocognitive deﬁcits (such as impaired RTs, at-
tention and memory) associated with adolescent can-
nabis use can persist after abstinence (Medina et al.
2007). As described by Schmidt & Roisier (2009) in
order to perform the SAT, participants must be able
to attend continuously for an extended period, use
working memory, learn probabilistic associations and
guide responses on the basis of such associations, all
of which may be impaired with cannabis use (Pope
et al. 2001; Scholes & Martin-Iverson, 2009). In order
to examine whether other cognitive processes (includ-
ing working memory, sustained attention, probabilistic
reversal learning) were inﬂuencing measures on the
SAT, Schmidt & Roisier (2009) performed a factor ana-
lysis using the SAT with a battery of cognitive tasks.
They found that the SAT could dissociate aberrant sa-
lience processing from other aspects of reward learning
and attention, although adaptive salience and learned
irrelevance were associated with each other. It is there-
fore unlikely that other aspects of cognitive function
that are affected by cannabis use are inﬂuencing the
current results, although these were not veriﬁed in
the current study. However, the cannabis users in
this study had faster RTs than non-users on both
high- and low-probability items in both blocks of the
SAT, suggesting that generalized psychomotor slowing
in cannabis users is unlikely to account for the current
results.
A potential limitation of the current study is that
participants consumed their own cannabis, rather
than a standard preparation. However, individuals
were tested whilst intoxicated and the levels of THC
in samples of the cannabis participants were using
were measured and it was conﬁrmed that the cannabis
contained high levels of THC. There was no ﬁxed inter-
val between cannabis exposure and SAT session,
meaning that heavier cannabis users may have had a
shorter interval between exposure and scan. It there-
fore remains possible that differences in the time
since last cannabis exposure, and therefore acute v.
chronic effects of cannabis, contribute to the differences
between the dependent/abuser and non-dependent
groups, rather than dependency and/or abuse per se.
The measures of substance use rely on self-report and
it was not possible to independently verify substance
use histories beyond ongoing cannabis use in the
user group and no recent use of other drugs in all
participants.
A recently published study (Bianconi et al. 2016)
found differences in cannabis-related experiences be-
tween patients with a ﬁrst episode of psychosis and
controls. The authors of that study reported that
patients with a ﬁrst episode of psychosis exhibit a
hypersensitivity to cannabis which not only involved
frequent ‘unpleasant experiences’ but also increased
‘enjoyable feelings’. The authors hypothesized that
that the increased positive reward acted as a reinforcer
to increase the risk of developing cannabis dependence
and counterbalancing the experience of unpleasant
effects. A large randomized, placebo-controlled study
found that THC increased paranoia by increasing
negative affect (i.e. anxiety) (Freeman et al. 2014). A
further limitation of this study would therefore be
that measures of anxiety, such as the Beck Anxiety
Inventory, were not recorded. However, taken together
with the current study, this suggests that heavy canna-
bis use may result in a combination of aberrant sali-
ence, anxiety, paranoia and amotivation (Bloomﬁeld
et al. 2014b), which might explain the increased risk
of schizophreniform psychosis. Future work should
therefore assess the relationships between both long-
term cannabis use and acute THC on psychotic symp-
toms, salience processing, paranoia, amotivation and
negative affect in order to examine this hypothesis.
Conclusion
These results suggest that cannabis dependence and
abuse are associated with increased aberrant salience
processing, and that within cannabis users there is a
positive relationship between explicit aberrant salience
and cannabis-induced psychotic symptom severity.
There is also evidence that long-term cannabis use is
associated with altered relationships between striatal
dopamine synthesis capacity and salience processing.
Long-term cannabis use may therefore increase the
risk of psychotic symptoms by increasing aberrant sa-
lience via disrupted striatal dopaminergic processing.
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The supplementary material for this article can be
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